Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Head and Neck Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 90 articles: HTML format

Single Articles

April 2024
1. WARDILL HR, Bossi P, Sonis ST
   Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis.
   J Clin Oncol. 2024;42:1436-1438.
   PubMed    
   
   
   
2. PENG X, Li Z, Pei Y, Zheng S, et al
   Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.
   J Clin Oncol. 2024;42:1426-1435.
   PubMed     Abstract available
   
   
   March 2024
3. LEE NY, Sherman EJ, Schoder H, Wray R, et al
   Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
   J Clin Oncol. 2024;42:940-950.
   PubMed     Abstract available
   
   
   
4. LIU M, Yang W, Guo C, Liu Z, et al
   Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.
   J Clin Oncol. 2024 Mar 8:JCO2301284. doi: 10.1200/JCO.23.01284.
   PubMed     Abstract available
   
   
   February 2024
5. ZHU M, Yoon HH
   Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
   J Clin Oncol. 2024;42:373-377.
   PubMed    
   
   
   January 2024
6. SUN R, Liu J, Wei LJ
   Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma.
   J Clin Oncol. 2024;42:366.
   PubMed    
   
   
   December 2023
7. 
   Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
   J Clin Oncol. 2023 Dec 19:JCO2302629. doi: 10.1200/JCO.23.02629.
   PubMed    
   
   
   November 2023
8. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
   Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
   J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
   PubMed     Abstract available
   
   
   October 2023
9. MOORE JL, Green M, Santaolalla A, Deere H, et al
   Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
   J Clin Oncol. 2023;41:4522-4534.
   PubMed     Abstract available
   
   
   
10. FARON M, Cheugoua-Zanetsie M, Tierney J, Thirion P, et al
    Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
    J Clin Oncol. 2023;41:4535-4547.
    PubMed     Abstract available
    
    
    September 2023
11. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    PubMed     Abstract available
    
    
    
12. KEAM B, Hong MH, Shin SH, Heo SG, et al
    Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    J Clin Oncol. 2023 Sep 12:JCO2202786. doi: 10.1200/JCO.22.02786.
    PubMed     Abstract available
    
    
    August 2023
13. GILLISON ML
    Flashback Foreword: Chemoradiotherapy for Nasopharyngeal Carcinoma.
    J Clin Oncol. 2023;41:3963-3964.
    PubMed    
    
    
    July 2023
14. LOU PJ, Jacky Lam WK, Hsu WL, Pfeiffer RM, et al
    Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches.
    J Clin Oncol. 2023 Jul 21:JCO2201979. doi: 10.1200/JCO.22.01979.
    PubMed     Abstract available
    
    
    June 2023
15. PARK JH, Hong JY, Shen JJ, Han K, et al
    Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
    J Clin Oncol. 2023;41:3363-3373.
    PubMed     Abstract available
    
    
    
16. KERMORGANT S
    Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol. 2023 Jun 15:JCO2300460. doi: 10.1200/JCO.23.00460.
    PubMed    
    
    
    
17. GILLISON ML
    Flashback Foreword: Human Papillomavirus and Incidence and Survival of Oropharyngeal Cancers.
    J Clin Oncol. 2023;41:3079-3080.
    PubMed    
    
    
    May 2023
18. EL ZARIF T, Nassar AH, Adib E, Fitzgerald BG, et al
    Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
    J Clin Oncol. 2023 May 16:JCO2202459. doi: 10.1200/JCO.22.02459.
    PubMed     Abstract available
    
    
    
19. XIE DX, Kut C, Quon H, Seiwert TY, et al
    Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer Network Guidelines.
    J Clin Oncol. 2023;41:2483-2487.
    PubMed    
    
    
    March 2023
20. YU G, Zhang N, Guan AJ, Qiao YW, et al
    Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma.
    J Clin Oncol. 2023 Mar 28:JCO2300057. doi: 10.1200/JCO.23.00057.
    PubMed    
    
    
    
21. BAUMAN JE, Saba NF, Roe D, Bauman JR, et al
    Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol. 2023 Mar 28:JCO2201994. doi: 10.1200/JCO.22.01994.
    PubMed     Abstract available
    
    
    
22. BURTNESS B
    First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
    J Clin Oncol. 2023 Mar 6:JCO2202349. doi: 10.1200/JCO.22.02349.
    PubMed    
    
    
    
23. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    PubMed     Abstract available
    
    
    February 2023
24. XU H, Zhang Y, Wu H, Zhou N, et al
    High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules.
    J Clin Oncol. 2023;41:1296-1306.
    PubMed     Abstract available
    
    
    
25. DING X, Zhang WJ, You R, Zou X, et al
    Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol. 2023 Feb 3:JCO2201450. doi: 10.1200/JCO.22.01450.
    PubMed     Abstract available
    
    
    January 2023
26. PATIL VM, Noronha V, Menon N, Singh A, et al
    Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
    J Clin Oncol. 2023 Jan 27:JCO2200980. doi: 10.1200/JCO.22.00980.
    PubMed     Abstract available
    
    
    
27. MO DC, Huang JF, Luo PH
    Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer.
    J Clin Oncol. 2023 Jan 20:JCO2202398. doi: 10.1200/JCO.22.02398.
    PubMed    
    
    
    December 2022
28. HO AL, Foster NR, Zoroufy AJ, Campbell JD, et al
    Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
    J Clin Oncol. 2022;40:4240-4249.
    PubMed     Abstract available
    
    
    
29. YILMAZ E, Ismaila N, Bauman JE, Dabney R, et al
    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
    J Clin Oncol. 2022 Dec 15:JCO2202328. doi: 10.1200/JCO.22.02328.
    PubMed     Abstract available
    
    
    
30. WU HX, Pan YQ, He Y, Wang ZX, et al
    Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
    J Clin Oncol. 2022 Dec 6:JCO2201490. doi: 10.1200/JCO.22.01490.
    PubMed     Abstract available
    
    
    
31. HADDAD RI, Harrington K, Tahara M, Ferris RL, et al
    Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
    J Clin Oncol. 2022 Dec 6:JCO2200332. doi: 10.1200/JCO.22.00332.
    PubMed     Abstract available
    
    
    November 2022
32. ROBBINS HA, Ferreiro-Iglesias A, Waterboer T, Brenner N, et al
    Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
    J Clin Oncol. 2022;40:3613-3622.
    PubMed     Abstract available
    
    
    October 2022
33. PATIL VM, Noronha V, Menon N, Rai R, et al
    Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
    J Clin Oncol. 2022 Oct 20:JCO2201015. doi: 10.1200/JCO.22.01015.
    PubMed     Abstract available
    
    
    
34. HO AL
    Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2022 Oct 12:JCO2201408. doi: 10.1200/JCO.22.01408.
    PubMed     Abstract available
    
    
    
35. HARRINGTON KJ, Burtness B, Greil R, Soulieres D, et al
    Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
    J Clin Oncol. 2022 Oct 11:JCO2102508. doi: 10.1200/JCO.21.02508.
    PubMed     Abstract available
    
    
    August 2022
36. MCLEOD DSA, Bedno SA, Cooper DS, Hutfless SM, et al
    Pre-existing Thyroid Autoimmunity and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study of US Active-Duty Personnel.
    J Clin Oncol. 2022;40:2578-2587.
    PubMed     Abstract available
    
    
    
37. MARON SB, Moya S, Morano F, Emmett MJ, et al
    Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    J Clin Oncol. 2022;40:2458-2467.
    PubMed     Abstract available
    
    
    July 2022
38. PATEL MA, Kratz JD, Lubner SJ, Loconte NK, et al
    Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102500. doi: 10.1200/JCO.21.02500.
    PubMed     Abstract available
    
    
    
39. PRICE JM, Mistry HB, Betts G, Cheadle EJ, et al
    Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:2203-2212.
    PubMed     Abstract available
    
    
    June 2022
40. ZHANG Y, Chen L, Hu GQ, Zhang N, et al
    Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2022 Jun 16:JCO2200327. doi: 10.1200/JCO.22.00327.
    PubMed     Abstract available
    
    
    
41. NORONHA V, Patil VM, Menon N, Prabhash K, et al
    Change in Pattern of Failure in Head and Neck Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200598. doi: 10.1200/JCO.22.00598.
    PubMed    
    
    
    
42. BROSE MS, Pryma DA, Newbold KL
    Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
    J Clin Oncol. 2022;40:1847-1849.
    PubMed    
    
    
    
43. HO AL, Dedecjus M, Wirth LJ, Tuttle RM, et al
    Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
    J Clin Oncol. 2022;40:1870-1878.
    PubMed     Abstract available
    
    
    May 2022
44. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Should Sentinel Lymph Node Biopsy Be Considered the New Standard of Care for Early-Stage Clinically Node-Negative Oral Squamous Cell Carcinoma?
    J Clin Oncol. 2022;40:1706-1709.
    PubMed    
    
    
    
45. MCDONALD AM, Lindeman B, Bahl D
    Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance.
    J Clin Oncol. 2022;40:1396-1399.
    PubMed    
    
    
    
46. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    PubMed     Abstract available
    
    
    April 2022
47. HAYES DN, Gleysteen JP, Schwartz DL
    For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting.
    J Clin Oncol. 2022 Apr 21:JCO2200274. doi: 10.1200/JCO.22.00274.
    PubMed    
    
    
    
48. SHEN L, Kato K, Kim SB, Ajani JA, et al
    Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2022 Apr 20:JCO2101926. doi: 10.1200/JCO.21.01926.
    PubMed     Abstract available
    
    
    
49. FRANCO AT, Ricarte-Filho JC, Isaza A, Jones Z, et al
    Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.
    J Clin Oncol. 2022;40:1081-1090.
    PubMed     Abstract available
    
    
    
50. FERRIS RL, Burtness B, Flamand Y
    Reply to A.S. Garden.
    J Clin Oncol. 2022;40:1133-1134.
    PubMed    
    
    
    
51. FAGIN JA
    Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer.
    J Clin Oncol. 2022;40:1124-1126.
    PubMed    
    
    
    March 2022
52. BURTNESS B, Rischin D, Greil R, Soulieres D, et al
    Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
    J Clin Oncol. 2022 Mar 25:JCO2102198. doi: 10.1200/JCO.21.02198.
    PubMed     Abstract available
    
    
    
53. MOWERY YM, Salama JK
    Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:814-817.
    PubMed    
    
    
    
54. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial.
    J Clin Oncol. 2022;40:866-875.
    PubMed     Abstract available
    
    
    
55. KIYOTA N, Tahara M, Mizusawa J, Kodaira T, et al
    Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 1:JCO2101293. doi: 10.1200/JCO.21.01293.
    PubMed     Abstract available
    
    
    February 2022
56. NG WT, Chua MLK, Lee AWM
    Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?
    J Clin Oncol. 2022 Feb 25:JCO2200099. doi: 10.1200/JCO.22.00099.
    PubMed    
    
    
    
57. GARDEN AS
    Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022 Feb 16:JCO2102630. doi: 10.1200/JCO.21.02630.
    PubMed    
    
    
    
58. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    PubMed     Abstract available
    
    
    January 2022
59. CHAUKAR D, Prabash K, Rane P, Patil VM, et al
    Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.
    J Clin Oncol. 2022;40:272-281.
    PubMed     Abstract available
    
    
    
60. MCDOWELL L, Magarey MJR, Rischin D
    Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:114-117.
    PubMed    
    
    
    
61. FERRIS RL, Flamand Y, Weinstein GS, Li S, et al
    Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    J Clin Oncol. 2022;40:138-149.
    PubMed     Abstract available
    
    
    
62. LI XY, Luo DH, Guo L, Mo HY, et al
    Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
    J Clin Oncol. 2022 Jan 6:JCO2101467. doi: 10.1200/JCO.21.01467.
    PubMed     Abstract available
    
    
    December 2021
63. HO AL
    Androgen Receptor Pathway in Salivary Gland Cancer.
    J Clin Oncol. 2021;39:4069-4072.
    PubMed    
    
    
    
64. LOCATI LD, Cavalieri S, Bergamini C, Resteghini C, et al
    Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.
    J Clin Oncol. 2021;39:4061-4068.
    PubMed     Abstract available
    
    
    
65. KEILTY D, Khandwala M, Liu ZA, Papaioannou V, et al
    Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children.
    J Clin Oncol. 2021;39:3813-3821.
    PubMed     Abstract available
    
    
    November 2021
66. XU B, Fuchs TL, Ahmadi S, Alghamdi M, et al
    International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    J Clin Oncol. 2021 Nov 3:JCO2101329. doi: 10.1200/JCO.21.01329.
    PubMed     Abstract available
    
    
    
67. ADENIS A, Kulkarni AS, Girotto GC, de la Fouchardiere C, et al
    Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    J Clin Oncol. 2021 Nov 3:JCO2100601. doi: 10.1200/JCO.21.00601.
    PubMed     Abstract available
    
    
    October 2021
68. SHAH MA, Hofstetter WL, Kennedy EB
    Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021;39:3182-3184.
    PubMed     Abstract available
    
    
    September 2021
69. POTTGEN C, Nestle U, Hocht S, Stuschke M, et al
    Interactions Between Dose and Volume in Chemoradiotherapy of Esophageal Cancer.
    J Clin Oncol. 2021 Sep 23:JCO2101579. doi: 10.1200/JCO.21.01579.
    PubMed    
    
    
    August 2021
70. KALRA B, Sinha S, Laskar SG
    De-Escalation in HPV: Near Yet Elusive.
    J Clin Oncol. 2021;39:2733-2734.
    PubMed    
    
    
    
71. CMELAK AJ, Ferris RL, Chen AM, Seiwert T, et al
    Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
    J Clin Oncol. 2021;39:2732-2733.
    PubMed    
    
    
    
72. HONG S, Zhang Y, Yu G, Peng P, et al
    Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    J Clin Oncol. 2021 Aug 11:JCO2100396. doi: 10.1200/JCO.21.00396.
    PubMed     Abstract available
    
    
    
73. LI B, Chen H
    The Best Surgery Should Be Applied for Locally Advanced Esophageal Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101340. doi: 10.1200/JCO.21.01340.
    PubMed    
    
    
    June 2021
74. GEIGER JL, Ismaila N, Beadle B, Caudell JJ, et al
    Management of Salivary Gland Malignancy: ASCO Guideline.
    J Clin Oncol. 2021;39:1909-1941.
    PubMed     Abstract available
    
    
    
75. HULSHOF MCCM, Geijsen ED, Rozema T, Oppedijk V, et al
    Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
    J Clin Oncol. 2021 Jun 8:JCO2003697. doi: 10.1200/JCO.20.03697.
    PubMed     Abstract available
    
    
    
76. GOODMAN KA, Ou FS, Hall NC, Bekaii-Saab T, et al
    Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003611. doi: 10.1200/JCO.20.03611.
    PubMed     Abstract available
    
    
    May 2021
77. HIRSHOREN N, Weinberger JM
    Surgical Perspective on Sentinel Node Biopsy for Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2021;39:1598-1599.
    PubMed    
    
    
    
78. LIU MA, Hsu WT, Johnstone C, Chang A, et al
    Interpreting the Clinical Utility of Early Interdisciplinary Supportive Care for Untreated Metastatic Esophageal Cancer.
    J Clin Oncol. 2021 May 7:JCO2100122. doi: 10.1200/JCO.21.00122.
    PubMed    
    
    
    
79. YOKOYAMA K, Ishiki H
    Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer.
    J Clin Oncol. 2021 May 5:JCO2100456. doi: 10.1200/JCO.21.00456.
    PubMed    
    
    
    April 2021
80. EYCK BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, et al
    Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
    J Clin Oncol. 2021 Apr 23:JCO2003614. doi: 10.1200/JCO.20.03614.
    PubMed     Abstract available
    
    
    
81. PEARSON AT, Vokes EE
    Is This the Dawn of Precision Oncology in Head and Neck Cancer?
    J Clin Oncol. 2021 Apr 20:JCO2100569. doi: 10.1200/JCO.21.00569.
    PubMed    
    
    
    
82. HASEGAWA Y, Tsukahara K, Yoshimoto S, Miura K, et al
    Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
    J Clin Oncol. 2021 Apr 20:JCO2003637. doi: 10.1200/JCO.20.03637.
    PubMed     Abstract available
    
    
    
83. MINAMI H, Kiyota N, Omori T
    Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?
    J Clin Oncol. 2021 Apr 12:JCO2003262. doi: 10.1200/JCO.20.03262.
    PubMed    
    
    
    March 2021
84. CHUNDURY A, Kim S
    Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?
    J Clin Oncol. 2021;39:947-949.
    PubMed    
    
    
    
85. YOM SS, Torres-Saavedra P, Caudell JJ, Waldron JN, et al
    Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    J Clin Oncol. 2021;39:956-965.
    PubMed     Abstract available
    
    
    January 2021
86. GEBRE-MEDHIN M, Brun E, Engstrom P, Haugen Cange H, et al
    ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    J Clin Oncol. 2021;39:38-47.
    PubMed     Abstract available
    
    
    
87. SEIWERT TY, Kiess AP
    Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1.
    J Clin Oncol. 2021;39:1-3.
    PubMed    
    
    
    
88. WIJNHOVEN BPL, Lagarde SM
    Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes.
    J Clin Oncol. 2021;39:90-91.
    PubMed    
    
    
    
89. NUYTENS F, Voron T, Piessen G
    Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE?
    J Clin Oncol. 2021;39:91-92.
    PubMed    
    
    
    December 2020
90. GARREL R, Poissonnet G, Moya Plana A, Fakhry N, et al
    Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:4010-4018.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.